Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

Teruo Inamoto; Jay B. Shah; Ashish M. Kamat

doi:10.1016/j.urolonc.2008.11.002

Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

Teruo Inamoto, Jay B. Shah, Ashish M. Kamat

Urology

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis-functions which have all been implicated in the pathogenesis of bladder cancer. One particular subtype, PPARγ, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer. In this review, we summarize the data available regarding relevance of PPARγ in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.

Original language	English (US)
Pages (from-to)	585-591
Number of pages	7
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	27
Issue number	6
DOIs	https://doi.org/10.1016/j.urolonc.2008.11.002
State	Published - Nov 2009

Keywords

Bladder cancer
Carcinogenesis
PPARγ
Peroxisome proliferator-activated receptor
Rosiglitazone

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2008.11.002

Cite this

@article{a9a54f2a80404e58a7298436c412c630,

title = "Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer",

abstract = "The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis-functions which have all been implicated in the pathogenesis of bladder cancer. One particular subtype, PPARγ, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer. In this review, we summarize the data available regarding relevance of PPARγ in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.",

keywords = "Bladder cancer, Carcinogenesis, PPARγ, Peroxisome proliferator-activated receptor, Rosiglitazone",

author = "Teruo Inamoto and Shah, {Jay B.} and Kamat, {Ashish M.}",

year = "2009",

month = nov,

doi = "10.1016/j.urolonc.2008.11.002",

language = "English (US)",

volume = "27",

pages = "585--591",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

AU - Inamoto, Teruo

AU - Shah, Jay B.

AU - Kamat, Ashish M.

PY - 2009/11

Y1 - 2009/11

N2 - The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis-functions which have all been implicated in the pathogenesis of bladder cancer. One particular subtype, PPARγ, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer. In this review, we summarize the data available regarding relevance of PPARγ in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.

AB - The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis-functions which have all been implicated in the pathogenesis of bladder cancer. One particular subtype, PPARγ, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer. In this review, we summarize the data available regarding relevance of PPARγ in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.

KW - Bladder cancer

KW - Carcinogenesis

KW - PPARγ

KW - Peroxisome proliferator-activated receptor

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=70350511393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350511393&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2008.11.002

DO - 10.1016/j.urolonc.2008.11.002

M3 - Review article

C2 - 19162510

AN - SCOPUS:70350511393

SN - 1078-1439

VL - 27

SP - 585

EP - 591

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 6

ER -

Friend or foe? Role of peroxisome proliferator-activated receptor-γ in human bladder cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this